Proprio Announces Research Collaboration with NYU Grossman School of Medicine

January 21, 2021

Proprio notes that Dr. John Golfinos, the Joseph P. Ransohoff Professor and Chair of the Department of Neurosurgery, will serve as the Project Director.

Dr. Golfinos will help guide research and the development of the company’s breakthrough imaging and navigation system for neurosurgical and spinal applications.

Proprio is pleased to have one of the nation’s leading academic neurosurgery programs as a research collaborator,” said Gabriel Jones, Co-Founder and CEO of Proprio. “We believe leading programs like NYU Grossman School of Medicine can play a key role in the design of surgeon-centric products. Working with their Department of Neurosurgery will help us bring to market an imaging and navigation system that lets surgeons focus on the patient in an entirely new way.”

“Our department has long been a leader in advancing patient care through revolutionary technology and world-class surgical technique,” said Dr. Golfinos. “We’re excited about the Proprio system’s potential to greatly improve the accuracy and efficiency of complex surgeries.”

The company notes as part of the collaboration, NYU Grossman School of Medicine neurosurgery residents and research fellows will have the opportunity to work with the Proprio technology development team at Proprio’s Seattle headquarters, contributing to product requirements, testing versions of the Proprio system, providing surgical guidance on product development, and conducting clinical studies. Proprio intends to place units at NYU for in situ studies upon receiving FDA clearance.

SourceProprio
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The AGENT DCB is available in Europe, parts of Asia Pacific and Latin America for the treatment of patients with ISR and previously untreated small vessel coronary disease. Boston Scientific plans to launch the technology in the U.S. in the coming months.
Tabrecta is the first FDA-approved therapy to treat non small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
The Cor® TRICUSPID ECM® valve has been successfully implanted in the 11th patient enrolled in the expansion by Dr. Marc Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the study.
Thirona notes LungQ 3.0.0 builds on 10 years of clinical trials and 200+ publications to deliver advanced segmentation of pulmonary segments and subsegments.
The Zeta Surgical Cranial Navigation System is a mixed-reality navigation system for neurosurgery, providing surgeons with "GPS-like" guidance with millimetric accuracy in real-time. Zeta's computer vision engine ensures maintained accuracy by automatically registering multiple times a second, accounting for patient movement, and allowing for awake and non-immobilized use in both operative and extra-operative settings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy